Income from operations of the pharma segment was at Rs 741 crore
The Board of Jubilant Life Sciences has approved the financial results for the quarter ended June 30, 2015. In Q1FY2016, the consolidated revenue is at Rs 1,459 crore, pharmaceuticals revenue at Rs 741 crore, contributing 51 per cent to the overall mix, LSI revenue at Rs 718 crore, contributing 49 per cent to the overall mix, international revenues at Rs 1,056 crore, contributing 72 per cent to the overall mix. EBITDA has been reported at Rs 333 crore, growing 123 per cent YoY with EBITDA margins at 22.8 per cent. Profit after tax is at Rs 128 crore, with an EPS of Rs 8.04 in the quarter.
In Q1 FY2016, income from operations of the pharma segment was at Rs 741 crore, contributing 51 per cent to the revenue mix. The segment EBITDA stood at Rs 225 crore, with EBITDA margins at 30.4 per cent. Key developed markets share was 87 per cent of total pharma segment revenues. Revenues from North America increased 35 per cent YoY to Rs 569 crore during the quarter. India business grew 41 per cent YoY while ROW business grew 26 per cent YoY.
In Q1 FY2016, income from operations of the life science ingredients segment stood at Rs 718 crore, contributing 49 per cent of the revenue mix. The segment EBITDA stood at Rs 121 crore, with EBITDA margins at 16.9 per cent. International markets contributed 49 per cent to the total LSI revenues with key developed markets share at 32 per cent of the total sales in the segment.
In Q1 FY2016, revenues from North America stood at Rs 619 crore, contributing 42 per cent to the overall revenues. Revenues from Europe and Japan stood at Rs 254 crore, contributing 17 per cent to the revenue mix. Domestic revenues stood at Rs 402 crore, thus contributing 28 per cent to the overall mix. Revenues in RoW including China was at Rs 184 crore, thus contributing 13 per cent to the overall mix.
Shyam S Bhartia, Chairman and Hari S Bhartia, Co-Chairman and Managing Director, Jubilant Life Sciences said, “Q1’16 results are, in many ways, a reflection of initiatives undertaken over the last few quarters. Our pharma segment has delivered strong results led by sustained performance in radiopharmaceuticals and API business. We are looking forward to improved performance in our CMO business, post successful completion of the inspection status during the quarter. In life science ingredients, we witnessed better margins across most businesses during the quarter. With some of the business related concerns now behind us, we believe that our performance is back on track and expect to continue the momentum going forward.”
Comments are closed.